Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MEDEVA PHARMA SUISSE A.G. et al v. ROXANE LABORATORIES, INC.
Case Number:
3:07-cv-05165
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 23, 2011
Roxane Agrees To Delay Launch Of Generic Asacol
A federal judge on Tuesday put a patent infringement suit over inflammatory bowel disorder drug Asacol on hold, following defendant generic-drug maker Roxane Laboratories Inc.'s agreement to delay the launch of a generic version of the drug until September.
-
January 31, 2011
Judge Sanctions Roxane In Asacol Patent Suit
A federal judge has ruled that Roxane Laboratories Inc. must pay some of the expert and attorneys' fees for the plaintiffs in a patent dispute over inflammatory bowel drug Asacol as punishment for concealing a batch of its generic version.
-
January 24, 2011
Protected Docs Still In Play In Generic Asacol Spat
A federal judge has overturned the rejection of Medeva Pharma Suisse AG and Warner Chilcott Pharmaceuticals Inc.'s bid to force generic-drug maker Roxane Laboratories Inc. to disclose allegedly confidential documents in their dispute over inflammatory bowel disorder drug Asacol.
-
March 12, 2010
Roxane Agrees To Hold Off On Generic Asacol
Roxane Laboratories Inc. has agreed to delay its launch of a generic version of inflammatory bowel drug Asacol until as late as November as part of a discovery agreement in a patent infringement suit brought by Procter & Gamble Pharmaceuticals Inc. and Medeva Pharma Suisse AG.